DE69809074T2 - Herstellung von arzneimitteln - Google Patents

Herstellung von arzneimitteln

Info

Publication number
DE69809074T2
DE69809074T2 DE69809074T DE69809074T DE69809074T2 DE 69809074 T2 DE69809074 T2 DE 69809074T2 DE 69809074 T DE69809074 T DE 69809074T DE 69809074 T DE69809074 T DE 69809074T DE 69809074 T2 DE69809074 T2 DE 69809074T2
Authority
DE
Germany
Prior art keywords
ethanol
composition
production
medicinal products
dissolved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69809074T
Other languages
English (en)
Other versions
DE69809074D1 (de
Inventor
Steven Leigh
Mathew Leigh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phares Pharmaceutical Research NV
Original Assignee
Phares Pharmaceutical Research NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phares Pharmaceutical Research NV filed Critical Phares Pharmaceutical Research NV
Application granted granted Critical
Publication of DE69809074D1 publication Critical patent/DE69809074D1/de
Publication of DE69809074T2 publication Critical patent/DE69809074T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
DE69809074T 1997-06-20 1998-06-19 Herstellung von arzneimitteln Expired - Lifetime DE69809074T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9713140A GB2326337A (en) 1997-06-20 1997-06-20 Homogeneous lipid compositions for drug delivery
PCT/GB1998/001803 WO1998058629A2 (en) 1997-06-20 1998-06-19 Preparation of pharmaceutical compositions

Publications (2)

Publication Number Publication Date
DE69809074D1 DE69809074D1 (de) 2002-12-05
DE69809074T2 true DE69809074T2 (de) 2003-06-26

Family

ID=10814725

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69809074T Expired - Lifetime DE69809074T2 (de) 1997-06-20 1998-06-19 Herstellung von arzneimitteln

Country Status (12)

Country Link
US (1) US6599527B1 (de)
EP (1) EP1011634B1 (de)
JP (1) JP2002507966A (de)
AT (1) ATE226815T1 (de)
AU (1) AU731397B2 (de)
CA (1) CA2294337C (de)
DE (1) DE69809074T2 (de)
DK (1) DK1011634T3 (de)
ES (1) ES2185179T3 (de)
GB (1) GB2326337A (de)
PT (1) PT1011634E (de)
WO (1) WO1998058629A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2326337A (en) 1997-06-20 1998-12-23 Phares Pharma Holland Homogeneous lipid compositions for drug delivery
GB2331924A (en) * 1997-12-08 1999-06-09 Phares Pharm Res Nv Lipid compositions and their use
AU2845599A (en) 1998-03-05 1999-09-20 Phares Pharmaceutical Research N.V. Pharmaceutical compositions and their use
EP1137402A1 (de) * 1998-12-08 2001-10-04 Phares Pharmaceutical Research N.V. Phospholipid-zusammensetzungen
GB9908309D0 (en) * 1999-04-12 1999-06-02 Phares Pharm Res Nv Lipid aggregate forming compositions and their use
EP1230917A1 (de) * 2001-02-08 2002-08-14 Vectron Therapeutics AG Invasomen zur Therapie von Erkrankungen, ihre Herstellung und Verwendung
KR101153459B1 (ko) 2002-06-12 2012-06-07 더 코카콜라 컴파니 식물성 스테롤을 함유하는 음료
US7306819B2 (en) 2002-06-12 2007-12-11 The Coca-Cola Company Beverages containing plant sterols
DE10233632A1 (de) * 2002-07-24 2004-02-05 Wilex Ag Formulierungen von Phenylalanin-Derivaten
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
US20050196370A1 (en) * 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
GB0317869D0 (en) * 2003-07-30 2003-09-03 Disperse Ltd Improved drug delivery system
EP1748759B1 (de) * 2004-04-27 2013-03-27 Javeri, Indu Verfahren zur verbesserung der wasserlöslichkeit von hydrophoben verbindungen durch mizellendispersionen
US7659310B2 (en) * 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
US20050255154A1 (en) 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
WO2005110360A2 (en) * 2004-05-18 2005-11-24 Phares Pharmaceutical Research N.V. Compositions for injection
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
US20110059549A1 (en) 2007-05-09 2011-03-10 Coleman Matthew A Methods and systems for producing nanolipoprotein particles
EP2008651A1 (de) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited Biologisch erodierbares Patch
EP2200613B1 (de) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazin-derivate und ihre verwendungen
WO2011038073A1 (en) * 2009-09-23 2011-03-31 Formatech, Inc. Methods for the preparation of liposomes comprising docetaxel
US20110070294A1 (en) * 2009-09-23 2011-03-24 Javeri Indu Methods for the Administration of Drugs Using Liposomes
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
US20130209550A1 (en) 2010-07-28 2013-08-15 Life Technologies Corporation Anti-Viral Azide Containing Compounds
PL2686017T3 (pl) 2011-03-14 2020-03-31 Drug Delivery Solutions Limited Kompozycja oftalmiczna
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
EP2807252B1 (de) 2012-01-26 2017-05-10 Life Technologies Corporation Verfahren zur erhöhung der infektiosität von viren
DE102012008822A1 (de) 2012-05-07 2013-11-07 GM Global Technology Operations LLC (n.d. Ges. d. Staates Delaware) Verstellvorrichtung, Kraftfahrzeugsitz, Kraftfahrzeug und Verfahren hierzu
CN104427976B (zh) 2012-05-10 2018-04-24 佩因拉佛姆有限公司 疏水的活性成分的储库制剂及其制备方法
WO2017044899A1 (en) 2015-09-11 2017-03-16 Lawrence Livermore National Security, Llc Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation
US20190307692A1 (en) * 2016-03-07 2019-10-10 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions methods and systems for improved drug loading
US11207422B2 (en) 2017-05-02 2021-12-28 Lawrence Livermore National Security, Llc MOMP telonanoparticles, and related compositions, methods and systems
EP3542788A1 (de) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topische zusammensetzung enthaltend calcipotriol und betamethason dipropionat

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB505983A (en) * 1937-11-17 1939-05-17 Ig Farbenindustrie Ag Improvements in the manufacture and production of pharmaceutically active substances
IT1202370B (it) * 1976-07-12 1989-02-09 Hoffmann La Roche Soluzioni inietabili in cui l'atti vita' emolitica degli agenti di formazione di micelle naturali e' evitata mediante l'aggiunta di lipoidi e relativi prodotti
US4298594A (en) 1978-04-14 1981-11-03 Arthur D. Little, Inc. Xenobiotic delivery vehicles, method of forming them and method of using them
CA1119955A (en) * 1978-04-14 1982-03-16 Little (Arthur D.), Inc. Xenobiotic delivery vehicles, method of forming them and method of using them
EP0117811A3 (de) 1983-02-23 1987-06-03 Sanofi S.A. Fungizide pharmazeutische Zusammensetzungen zur oralen Verabreichung
DE3585967D1 (de) 1984-03-08 1992-06-11 Phares Pharma Holland Liposombildende zusammensetzung.
US5141674A (en) * 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
US4830858A (en) * 1985-02-11 1989-05-16 E. R. Squibb & Sons, Inc. Spray-drying method for preparing liposomes and products produced thereby
JPS62279832A (ja) * 1986-05-27 1987-12-04 Kyowa Hakko Kogyo Co Ltd 乳化剤の製法
US5009956A (en) * 1987-02-24 1991-04-23 Univ Minnesota Phospholipase A2-resistant liposomes
NZ223660A (en) * 1987-03-05 1990-11-27 Liposome Co Inc Low toxicity drug-lipid complexes; methods of making them; and method of determining their toxicity
CA1323306C (en) 1987-03-05 1993-10-19 Mircea C. Popescu Pharmacological agent-lipid solution preparation
US4828837A (en) * 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
HU205010B (en) * 1987-09-15 1992-03-30 Sandoz Ag Process for producing pharmaceutical compositions comprising compounds soluble up to 1 per cent and having medical activity
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US5178875A (en) * 1991-01-14 1993-01-12 The Board Of Regents, The University Of Texas System Liposomal-polyene preliposomal powder and method for its preparation
US5043164A (en) * 1989-01-17 1991-08-27 The University Of Tennessee Research Corporation Blood-stable, cholesterol-free liposomes
US5221696A (en) * 1989-03-29 1993-06-22 Alcon Laboratories, Inc. Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs
JP2785981B2 (ja) * 1989-11-20 1998-08-13 株式会社資生堂 乳化組成物
DE4003782C2 (de) * 1990-02-08 1999-03-11 Nattermann A & Cie Liposomales System und Verfahren zu dessen Herstellung
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US5529785A (en) * 1993-05-12 1996-06-25 Dietl; Hans Pharmaceutical preparation containing cyclosporin(s) for oral administration and process for producing same
DE19609538A1 (de) * 1996-03-11 1997-09-18 Basf Ag Feinverteilte Carotinoid- und Retinoidsuspensionen und Verfahren zu ihrer Herstellung
AU6833994A (en) * 1993-05-17 1994-12-12 Liposome Company, Inc., The Incorporation of taxol into liposomes and gels
US5693337A (en) * 1994-07-13 1997-12-02 Wakamoto Pharmaceutical Co., Ltd. Stable lipid emulsion
EP0697214A1 (de) 1994-07-19 1996-02-21 Vestar, Inc. Pharmazeutische Formulierungen mit liposomalem Cyclosporin
HU215966B (hu) * 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
EP0760237A1 (de) * 1995-08-30 1997-03-05 Cipla Limited Öl-in-Wasser-Mikroemulsionen
US5886003A (en) * 1996-03-25 1999-03-23 Eli Lilly And Company Methods of treating or ameliorating the symptoms of venomous bites and stings
CN1246058A (zh) * 1997-01-30 2000-03-01 诺瓦提斯公司 包含环孢菌素a的无油药物组合物
GB2326337A (en) 1997-06-20 1998-12-23 Phares Pharma Holland Homogeneous lipid compositions for drug delivery

Also Published As

Publication number Publication date
EP1011634B1 (de) 2002-10-30
PT1011634E (pt) 2003-03-31
AU731397B2 (en) 2001-03-29
GB2326337A (en) 1998-12-23
DE69809074D1 (de) 2002-12-05
US6599527B1 (en) 2003-07-29
CA2294337A1 (en) 1998-12-30
WO1998058629A2 (en) 1998-12-30
JP2002507966A (ja) 2002-03-12
GB9713140D0 (en) 1997-08-27
WO1998058629A3 (en) 1999-03-18
ATE226815T1 (de) 2002-11-15
EP1011634A1 (de) 2000-06-28
AU8118498A (en) 1999-01-04
ES2185179T3 (es) 2003-04-16
CA2294337C (en) 2007-05-15
DK1011634T3 (da) 2003-03-03

Similar Documents

Publication Publication Date Title
DE69809074T2 (de) Herstellung von arzneimitteln
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
DE50005515D1 (de) Mechanisch stabile pharmazeutische darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive substanzen
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
DE60041976D1 (de) Phenoxycarbonsäureverbindungen und zusammensetzungen zur verabreichung aktiver wirkstoffe
ATE202931T1 (de) Taxanderivate enthaltende arzneizubereitungen
ATE224717T1 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
DE3783356T2 (de) Benzimidazolderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate.
DE3669106D1 (de) Pharmazeutische zusammensetzungen mit gehalt an flavanolignanen und phospholipiden als wirkstoffe.
DE68909100D1 (de) Physiologisch wirkende Substanzen, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen davon.
SE9704400D0 (sv) Porous inorganic particles as carriers for drug substances
DK0584126T3 (da) Lanolinderivater som penetrationsfremmende stoffer
DE3783923T3 (de) Einen Wirkstoff und ein in Wasser quellendes Polymer enthaltendes Arzneimittel.
TR200401462T4 (tr) Torsemid modifikasyonu II' yi içeren dengeli bir farmasötik formülasyonu
HUP0004362A2 (hu) Karbamazepint vagy származékait tartalmazó parenterális készítmények
ATE301452T1 (de) Verfahren zur herstellung einer flüssigen dosierungseinheit und kit
GEP20053581B (en) Pharmaceutical Composition and Method for Preparation Thereof
ATE64307T1 (de) Injizierbare arzneiformulierungen von substanzen mit allgemeiner anaesthetischer wirkung.
ATE212840T1 (de) Oral anzuwendende feste arzneizubereitungen mit modulierter wirkstoffabgabe enthaltend nicorandil und verfahren zu deren herstellung
ATE301453T1 (de) Injizierbare arzneiformulierungen von partricin derivaten
KR870005642A (ko) 디플루니살과 트로메타민의 혼합물
KR970032876A (ko) 간장질환 치료용 의약 조성물
KR950031082A (ko) 우르소데옥시콜린산의 신규한 유도체와 이를 포함하는 제약학적 성분물
ES2087834B1 (es) Nuevas composiciones laxantes y su procedimiento de obtencion.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition